Byeong Hee Hwang
University of California, Santa Barbara
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Byeong Hee Hwang.
Journal of Controlled Release | 2013
Vivek Gupta; Byeong Hee Hwang; Nishit Doshi; Samir Mitragotri
Delivery of therapeutic macromolecules is limited by the physiological limitations of the gastrointestinal tract including poor intestinal permeability, low pH and enzymatic activity. Several permeation enhancers have been proposed to enhance intestinal permeability of macromolecules; however their utility is often hindered by toxicity and limited potency. Here, we report on a novel permeation enhancer, Dimethyl palmitoyl ammonio propanesulfonate (PPS), with excellent enhancement potential and minimal toxicity. PPS was tested for dose- and time-dependent cytotoxicity, delivery of two model fluorescent molecules, sulforhodamine-B and FITC-insulin in vitro, and absorption enhancement of salmon calcitonin (sCT) in vivo. Caco-2 studies revealed that PPS is an effective enhancer of macromolecular transport while being minimally toxic. TEER measurements in Caco-2 monolayers confirmed the reversibility of the effect of PPS. Confocal microscopy studies revealed that molecules permeate via both paracellular and transcellular pathways in the presence of PPS. In vivo studies in rats showed that PPS enhanced relative bioavailability of sCT by 45-fold after intestinal administration. Histological studies showed that PPS does not induce damage to the intestine. PPS is an excellent permeation enhancer which provides new opportunities for developing efficacious oral/intestinal delivery systems for therapeutic macromolecules.
Journal of Controlled Release | 2013
Vivek Gupta; Byeong Hee Hwang; JooHee Lee; Aaron C. Anselmo; Nishit Doshi; Samir Mitragotri
One of the major challenges faced by therapeutic polypeptides remains their invasive route of delivery. Oral administration offers a potential alternative to injections; however, this route cannot be currently used for peptides due to their limited stability in the stomach and poor permeation across the intestine. Here, we report mucoadhesive devices for oral delivery that are inspired by the design of transdermal patches and demonstrate their capabilities in vivo for salmon calcitonin (sCT). The mucoadhesive devices were prepared by compressing a polymeric matrix containing carbopol, pectin and sodium carboxymethylcellulose (1:1:2), and were coated on all sides but one with an impermeable and flexible ethyl cellulose (EC) backing layer. Devices were tested for in vitro dissolution, mucoadhesion to intestinal mucosa, enhancement of drug absorption in vitro (Caco-2 monolayer transport) and in vivo in rats. Devices showed steady drug release with ≈75% cumulative drug released in 5h. Devices also demonstrated strong mucoadhesion to porcine small intestine to withstand forces up to 100 times their own weight. sCT-loaded mucoadhesive devices exhibited delivery of sCT across Caco-2 monolayers and across the intestinal epithelium in vivo in rats. A ≈52-fold (pharmacokinetic) and ≈44-fold (pharmacological) enhancement of oral bioavailability was observed with mucoadhesive devices when compared to direct intestinal injections. Oral delivery of devices in enteric coated capsules resulted in significant bioavailability enhancement.
Journal of Controlled Release | 2015
Dilip Paithankar; Byeong Hee Hwang; Girish Munavalli; Arielle Kauvar; Jenifer Lloyd; Richard Blomgren; Linda Faupel; Todd J. Meyer; Samir Mitragotri
Recent advances in nanotechnology have provided numerous opportunities to transform medical therapies for the treatment of diseases including cancer, atherosclerosis, and thrombosis. Here, we report, through in vitro studies and in vivo human pilot clinical studies, the use of inert, inorganic silica-gold nanoshells for the treatment of a widely prevalent and researched, yet poorly treated disease of acne. We use ~150nm silica-gold nanoshells, tuned to absorb near-IR light and near-IR laser irradiation to thermally disrupt overactive sebaceous glands in the skin which define the etiology of acne-related problems. Low-frequency ultrasound was used to facilitate deep glandular penetration of the nanoshells. Upon delivery of the nanoshells into the follicles and glands, followed by wiping of superficial nanoshells from skin surface and exposure of skin to near-infrared laser, nanoshells localized in the follicles absorb light, get heated, and induce focal thermolysis of sebaceous glands. Pilot human clinical studies confirmed the efficacy of ultrasonically-delivered silica-gold nanoshells in inducing photothermal disruption of sebaceous glands without damaging collateral skin.
European Journal of Pharmaceutical Sciences | 2013
Sumit Paliwal; Byeong Hee Hwang; Kenneth Y. Tsai; Samir Mitragotri
Drug Delivery and Translational Research | 2012
Byeong Hee Hwang; Nishit Doshi; Kenneth Y. Tsai; Samir Mitragotri
Archive | 2012
Byeong Hee Hwang; Samir Mitragotri; Russell M. Lebovitz
Drug Delivery and Translational Research | 2013
Byeong Hee Hwang; Kenneth Y. Tsai; Samir Mitragotri
Archive | 2012
Samir Mitragotri; Russell M. Lebovitz; Byeong Hee Hwang
Archive | 2017
Byeong Hee Hwang; Russell M. Lebovitz; Samir Mitragotri
한국생물공학회 학술대회 | 2015
Byeong Hee Hwang; Dilip Paithankar; Girish Munavalli; Arielle Kauvar; Jenifer Lloyd; Richard Blomgren; Linda Faupel; Todd J. Meyer; Samir Mitragotri